Liquid Biopsy: Page 2

GC Genome liquid biopsy technology in study predicts solid tumor radiation therapy response

By LabPulse.com staff writers

The research conducted in collaboration with the Samsung Medical Center, Sungkyunkwan University School of Medicine, used I-score, a tool for calculating genomic instabilities developed by GC Genome.

April 10, 2023

OraSure, nRichDx to offer products for researchers developing urine-based liquid biopsy assays

By LabPulse.com staff writers

The firms noted that their products use first-void urine, which is enriched in biomarkers suitable for molecular analysis by people researching sexually-transmitted infections, human papillomavirus, and early stage cancers.

March 27, 2023

Guardant Health, Ohio State University study colorectal cancer screening adherence

By LabPulse.com staff writers

The Ohio State University-led study will evaluate changes in CRC screening adherence in underserved urban and rural communities. Guardant Health is providing its Shield blood test to eligible individuals through mobile health clinic partners.

March 21, 2023

Natera receives commercial payor coverage for molecular residual disease test

By LabPulse.com staff writers

Among the first commercial coverage policies for the test, Blue Shield of California began providing coverage of Signatera for plan members diagnosed with solid tumors.

March 2, 2023

UnitedHealthcare increases coverage for Guardant360 CDx liquid biopsy test

By LabPulse.com staff writers

The new policy coverage by UnitedHealthcare is in addition to coverage for the liquid biopsy CDx test under UHC Medicare Advantage policies for comprehensive genomic profiling of all solid tumors.

February 8, 2023

Geneseeq nabs CE Marks for minimal residual disease, early cancer detection tests

By LabPulse.com staff writers

The firm has received CE Marks for liquid biopsy multicancer minimal residual disease detection and multicancer early detection kits to detect patients with solid tumors.

January 24, 2023

Agilent, Quest extend access to NGS liquid biopsy CDx for NSCLC

By LabPulse.com staff writers

The agreement between Agilent and Quest aims to enable broader adoption of ctDx First, a single-site premarket approved test performed at the Resolution Bioscience CLIA-certified laboratory in Kirkland, WA.

January 23, 2023

$1.3 billion liquid biopsy market represents the present and future of clinical oncology: Kalorama

By Bruce Carlson

The liquid biopsy market can be segmented by the type of analyte detected and analyzed. There are four main categories: circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes and other analytes, and multiple analytes.

January 19, 2023

FoundationOne Liquid CDx receives FDA approval for use with Rozlytrek (entrectinib)

By LabPulse.com staff writers

The CDx is indicated for use with patients who do not have a tissue sample available and may be appropriate for treatment with Rozlytrek (entrectinib), a targeted therapy developed by Genentech.

January 4, 2023

Aptorum Group announces publication on metagenomics sequencing workflow on Illumina platforms

By LabPulse.com staff writers

The paper, entitled “Towards a rapid-turnaround low-depth unbiased metagenomics sequencing workflow on the Illumina platforms,” is available as a preprint on medRxiv.

January 4, 2023

Datar Cancer Genetics obtains FDA breakthrough device designation for blood test to detect inaccessible brain tumors

By LabPulse.com staff writers

A prospective, blinded study by London’s Imperial College researchers showed the TriNetra-Glio liquid biopsy test, which requires 15 mL of blood, can detect malignant brain tumors.

January 3, 2023

Burning Rock nabs FDA breakthrough device designation for multicancer detection blood test

By LabPulse.com staff writers

The test, called OverC MCDBT, is intended for early detection of esophageal, liver, lung, ovarian, and pancreatic cancers in adults of either sex from 50 to 75 years of age and at average risk for cancer.

January 3, 2023

Previous Page

Page 2 of 4

Next Page